Example: Heart Attack

Search clinical trials for: Antibodies, Monoclonal

Total 4103 results

NCT02838823

Completed

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Conditions: Breast Cancer
NCT02836795

Active, not recruiting

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Conditions: Melanoma; Urological Cancer
NCT04430166

Not yet recruiting

PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma

Conditions: Lymphoepithelioma-Like Carcinoma
NCT03405272

Unknown status

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Conditions: Metastatic Colorectal Cancer
NCT04662788

Not yet recruiting

Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

Conditions: Hematological Malignancies
NCT00610857

Completed

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

Conditions: Melanoma
NCT04702009

Not yet recruiting

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Conditions: Advanced Lung Carcinoma; Non-small Cell Lung Cancer
NCT03167853

Completed

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

Conditions: Neuroendocrine Tumors
NCT02460393

Completed

A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects

Conditions: Rheumatoid Arthritis
NCT04326296

Not yet recruiting

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Conditions: Colorectal Neoplasms
NCT02857166

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Conditions: Solid Tumors
NCT02912247

Completed

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

Conditions: Healthy
NCT02206308

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

Conditions: B-cell Non Hodgkin's Lymphoma
NCT03713905

Enrolling by invitation

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors
NCT01419834

Active, not recruiting

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Conditions: Neuroblastoma
NCT04441918

Recruiting

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

Conditions: COVID-19; and High Infection Risk of SARS-CoV-2
NCT00775502

Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Conditions: Multiple Myeloma
NCT02245867

Completed

Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Conditions: Amyloidosis
NCT03113266

Recruiting

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Conditions: Bladder Urothelial Carcinoma
NCT03013101

Active, not recruiting

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Conditions: Advanced Melanoma; Metastatic Melanoma
NCT03086174

Active, not recruiting

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Conditions: Kidney Cancer Stage Iv; Advanced Melanoma
NCT03704246

Unknown status

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Conditions: Advanced Solid Tumor
NCT02211443

Unknown status

Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer
NCT03550508

Unknown status

Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors

Conditions: Bone Metastases
NCT00023933

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

Conditions: Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer